Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Dr Michael Baker, CEO of Suda Pharmaceuticals (ASX:SUD).

Suda is developing oral, spray mist versions of common drugs in order to improve their efficacy by delivering them more directly to the blood stream via the mouth lining.

Reformulations under development include the erectile dysfunction drug Viagra and the insomnia drug Stilnox.

The company is also working with other partners including Zelira Therapeutics on spray versions of medicinal cannabis.

So tune in to hear the pair discuss the potential upside for a shift towards oral drug delivery.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!

Read MoreDrug DevelopmentHealth

Featured Companies

You might be interested in